TLR signaling is activated in lymph-node resident CLL cells and is only partially inhibited by ibrutinib Conflicts of Interest (original) (raw)
Related papers
Cancer Research, 2018
Achilles Anagnostopoulos, Chrysoula Belessi
The Journal of Immunology, 2014
Sensitization of IL2 Signaling through TLR-7 Enhances B Lymphoma Cell Immunogenicity
Ibrutinib treatment improves T cell number and function in CLL patients
The Journal of clinical investigation, 2017
New insights into the regulation of TLR signaling
Journal of Leukocyte Biology, 2006
TLR2 Expression on Leukemic B Cells from Patients with Chronic Lymphocytic Leukemia
Archivum immunologiae et therapiae experimentalis, 2018
Lymphoma Cell Immunogenicity through TLR-7 Enhances B Sensitization of IL2 Signaling
Molecular and cellular mechanisms of CLL: novel therapeutic approaches
Nature Reviews Clinical Oncology, 2009
Immune Response Activation, 2014
Human Lymphatic Endothelial Cells Express Multiple Functional TLRs
The Journal of Immunology, 2008
TLR agonists: our best frenemy in cancer immunotherapy
Journal of Leukocyte Biology, 2013
The role of TLR activation in inflammation
The Journal of Pathology, 2008
2008
Critical molecular pathways in CLL therapy
Molecular medicine (Cambridge, Mass.), 2018
A phase I/II trial of TLR-7 agonist immunotherapy in chronic lymphocytic leukemia
Leukemia, 2009
Regulation of T cell activation by TLR ligands
European Journal of Cell Biology, 2011
2021
Cleaved/Associated TLR3 Represents the Primary Form of the Signaling Receptor
Toufic Renno, M. Bonnin, Jean-jacques Pin
The Journal of Immunology, 2013
Cancers
Immunomodulatory effects of Toll-like receptor-7 activation on chronic lymphocytic leukemia cells
Leukemia, 2006
Blood, 2008